CORMEDIX INC. Adjustments to Additional Paid in Capital, Other
CORMEDIX INC. (CRMD) reported Adjustments to Additional Paid in Capital, Other of $1.33 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-27.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2013-03-27
- CORMEDIX INC. adjustments to additional paid in capital, other for the quarter ending 2012-12-31 was $632.29K.
- CORMEDIX INC. adjustments to additional paid in capital, other for fiscal 2012 was $1.33M.
- CORMEDIX INC. adjustments to additional paid in capital, other for fiscal 2009 was $1.24M, a 65.72% increase from fiscal 2008.
- CORMEDIX INC. adjustments to additional paid in capital, other for fiscal 2008 was $747.22K, a 75.04% decline from fiscal 2007.
- CORMEDIX INC. adjustments to additional paid in capital, other for fiscal 2007 was $2.99M.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|
| 2012-12-31 | $632.29K derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-03-27 | $1.33M 10-K · filed 2013-03-27 | |
| 2012-09-30 | $701.02K 10-Q/A · filed 2013-03-27 | ||
| 2009-12-31 | $1.24M 10-K · filed 2013-03-27 | ||
| 2008-12-31 | $747.22K 10-K · filed 2013-03-27 | ||
| 2007-12-31 | $2.99M 10-K · filed 2013-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |